BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Ignite II - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://gmkb.org
X-WR-CALDESC:Events for Ignite II
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240208T140000
DTEND;TZID=America/New_York:20240208T150000
DTSTAMP:20260425T163352
CREATED:20240108T025319Z
LAST-MODIFIED:20240108T025711Z
UID:3821-1707400800-1707404400@gmkb.org
SUMMARY:Duke Genomic Seminar Series
DESCRIPTION:A platform approach to develop and deploy CRISPR-Cas based experimental therapies for inborn errors of immunity in an academic/nonprofit setting \nThursday\, February 8 | 2-3 p.m. ET | Bryan Neurobiology Research Building\, Rm 103 \nSpeaker: Fyodor Urnov\, PhD\nProfessor of Molecular & Cellular Biology\, University of California\, Berkeley\nDirector of Technology & Translation\, Innovative Genomics Institute \nThe vast majority of diseases clinically tractable by genome editing using current-state technology are not the targets of active preclinical or clinical development. Addressing this issue will require more involvement of the academic/nonprofit sector\, but despite an existing charted path for advancing genome editing of specific cell types and tissues (such as T cells\, hematopoietic stem cells\, the liver\, and the retina) to the clinic\, there presently is only one open US IND for genome editing by an all-academic group. A key reason is that the current manufacturing\, regulatory\, and healthcare economics environment is not configured to maximize clinical impact of a technology like CRISPR-Cas. Under the framework that exists today\, a pediatric patient newly diagnosed with a terminal illness such as a severe inborn error of immunity due to a never-before-seen but clinically editable mutation and a life expectancy of < 1 yr will have to wait ~3.5 years until a gene editing medicine is engineered\, tested\, and manufactured at an approximate total cost of $9m. An actionable path through this status quo is to develop and clinically derisk a dedicated nonclinical development path for use in academic/nonprofit settings in N=1/rare situations of dire medical need. From a technology standpoint\, this will require comprehensive leveraging of the intrinsically platform nature of CRISPR-Cas gene editing. The Innovative Genomics Institute in close partnership with clinicians at UCSF and UCLA is developing such a platform focused on inborn errors of immunity\, where ca 112\,000 known patients suffering from 505 currently known diseases lack even a single open trial for genome editing open at the present time. \nTo learn more\, visit Duke’s Genomic Seminar Series page. \nPlease note: This seminar series occurs quarterly with some events occurring virtually only and others in-person with streaming options.
URL:https://gmkb.org/event/duke-genomic-seminar-series/
LOCATION:Duke Neurobiology Research Center\, 311 Research Drive\, Durham\, NC\, 27710\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240215T090000
DTEND;TZID=America/New_York:20240215T100000
DTSTAMP:20260425T163352
CREATED:20240209T230341Z
LAST-MODIFIED:20240209T230341Z
UID:3874-1707987600-1707991200@gmkb.org
SUMMARY:Personalized Therapeutics: Clinical Reality and Future Challenges
DESCRIPTION:Personalized Therapeutics: Clinical Reality and Future Challenges \nThursday\, February 15 | 9 a.m. ET | Virtual \nSpeaker: George P. Patrinos \nDr. Patrinos is a professor of pharmacogenomics and pharmaceutical biotechnology in the University of Patras’ (Greece) Department of Pharmacy\, and holds adjunct professorships at Erasmus MC\, Faculty of Medicine\, Rotterdam (the Netherlands) and the United Arab Emirates University\, College of Medicine\, Department of Genetics and Genomics\, Al-Ain (UAE). He also served for 12.5 years as full member and Greece’s National Representative in the CHMP Pharmacogenomics Working Party of the European Medicines Agency (EMA) and as Chair of the Global Genomic Medicine Collaborative (G2MC) since 2018. \nAbout the Talk: This talk will provide a summary of the PREPARE and Em-HEART clinical studies in psychiatry and cardiology\, and ethical and regulatory challenges in the field of pharmacogenomics. \nTo learn more and register\, visit the GGMC Educational Webinar Series webpage. \nPlease note: Registration is required.
URL:https://gmkb.org/event/personalized-therapeutics-clinical-reality-and-future-challenges/
LOCATION:Virtual
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240215T130000
DTEND;TZID=America/New_York:20240215T140000
DTSTAMP:20260425T163352
CREATED:20231229T052112Z
LAST-MODIFIED:20231229T052112Z
UID:3800-1708002000-1708005600@gmkb.org
SUMMARY:Population Screening for Hereditary Hemochromatosis More than a Quarter Century After Gene Discovery – Current Status and the Path Forward
DESCRIPTION:Population Screening for Hereditary Hemochromatosis More than a Quarter Century After Gene Discovery –\nCurrent Status and the Path Forward \nThursday\, February 15 | 1-2 p.m. ET | Virtual \nSpeakers: Paul C. Adams\, MD\, Professor\, Division of Gastroenterology\, Western University \nGail P. Jarvik\, MD\, PhD\, Head and Professor\, Division of Medical Genetics\, University of Washington \nKris V. Kowdley\, MD\, FACP\, FACG\, AGAF\, FAASLD\, Director\, Liver Institute Northwest \nIn this webinar\, speakers will discuss how knowledge about hereditary hemochromatosis (HH) has evolved since the discovery of the HFE gene in 1997\, current opportunities for clinical and public health action to prevent disease\, and future research priorities to advance case detection and reduce clinical complications from HH. \nTo learn more and register\, visit the CDC events page. \nPlease note: Registration is required for this webinar.
URL:https://gmkb.org/event/population-screening-for-hereditary-hemochromatosis-more-than-a-quarter-century-after-gene-discovery-current-status-and-the-path-forward/
LOCATION:Virtual
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240228T120000
DTEND;TZID=America/New_York:20240228T130000
DTSTAMP:20260425T163352
CREATED:20240226T030620Z
LAST-MODIFIED:20240226T030731Z
UID:3896-1709121600-1709125200@gmkb.org
SUMMARY:Immune (check point) Related Adverse Events
DESCRIPTION:Immune (check point) Related Adverse Events \nWednesday\, February 28 | 12 p.m. ET | Online \nSpeaker: Frances Collichio\, MD\, Professor of Medicine\, UNC Chapel Hill \nDr. Collichio will review the common and uncommon side effects of immune check point inhibitors. She will also discuss the relatively new concept of delayed immune related events. \nTo learn more and register\, visit the event webpage. \nPlease note: Registration is required for this webinar.
URL:https://gmkb.org/event/immune-check-point-related-adverse-events/
LOCATION:Virtual
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240229T090000
DTEND;TZID=America/New_York:20240229T100000
DTSTAMP:20260425T163352
CREATED:20231106T001846Z
LAST-MODIFIED:20240226T010923Z
UID:3593-1709197200-1709200800@gmkb.org
SUMMARY:Translating Science from Bench to Bedside: A Case for Extracellular Vesicles
DESCRIPTION:Translating Science from Bench to Bedside: A Case for Extracellular Vesicles \nThursday\, February 29 | 9 a.m. ET | Online \nSpeaker: Dr. Carlos Salomon Gallo \nDr. Salomon is the head of the Translational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group\, NHMRC Investigator Fellow and is considered a worldwide authority on extracellular vesicles (EVs) biomarkers for complications of pregnancies and ovarian cancer (OC). In the last 10 years\, Dr. Salomon’s primary research and commercialization activities have focused on the identification and validation of biomarkers\, and development of In Vitro Multivariate Index Assays for clinically relevant complications (including ovarian cancers\, and obstetrical syndromes) and their translation into clinical applications. He is a pioneer in investigating the release of EVs by the placenta and tumor cells and their utility as a biomarker for a wide range of pregnancy complications and OC. \nThis talk will cover the burgeoning field of EVs signaling holds the potential to revolutionize our understanding of cancer biology and offers new avenues for non-invasive diagnostics and therapeutic interventions. EVs have been implicated in various aspects of cancer progression\, including tumor initiation\, metastasis\, and response to therapy. From the early stages of tumor development\, tumor-derived EVs are detectable in the circulation. \nTo learn more and register\, visit the GGMC Educational Webinar Series webpage. \nPlease note: Registration is required for this webinar. \n 
URL:https://gmkb.org/event/translating-science-from-bench-to-bedside-a-case-for-extracellular-vesicles/
LOCATION:Virtual
END:VEVENT
END:VCALENDAR